Last reviewed · How we verify
Mexenon (MEXENONE)
Mexenon (generic name: MEXENONE) is a drug. It is currently in Phase 2 development.
Mexenon is a small molecule modality that works by interacting with a specific biological target to produce a therapeutic effect.
Mexenon (MEXENONE) is a small molecule modality developed by an unknown entity, currently owned by an unknown entity. Its target and drug class are unknown, and it has not been approved by the FDA for any indications. The commercial status of Mexenon is unclear, and it is not known whether it is patented or available as a generic. Further information on Mexenon's pharmacokinetics, safety considerations, and clinical use is not available. As a result, Mexenon is not a recognized treatment option in the pharmaceutical industry.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | MEXENONE |
|---|---|
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Mechanism of action
Imagine Mexenon as a key that fits into a lock on a cell. When it binds to the lock, it triggers a series of events that ultimately lead to a desired outcome, such as reducing inflammation or blocking a disease-causing process. However, without more information on Mexenon's target and mechanism of action, it is difficult to provide a more detailed explanation.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mexenon CI brief — competitive landscape report
- Mexenon updates RSS · CI watch RSS
Frequently asked questions about Mexenon
What is Mexenon?
How does Mexenon work?
What is the generic name of Mexenon?
What development phase is Mexenon in?
Related
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing